Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
STAAR Surgical (STAA): Broadwood Partners filed a DFAN14A updating its campaign website for the ongoing proxy contest tied to the proposed sale to Alcon. The update attaches and incorporates three exhibits: a Yunqi Capital letter to STAAR’s board and a media article outlining recent developments.
Exhibit highlights: The Yunqi Capital letter dated October 31, 2025 urges termination of the Alcon transaction and notes the special meeting was postponed. An Investing.com article states STAAR asked Alcon to increase its $28-per-share offer and that Alcon rejected the request. The article also reports STAAR’s board discussed potential amendments, including a 45‑day “go‑shop,” and moved the special meeting to December 3, 2025. It further notes that ISS, Glass Lewis, and Egan‑Jones recommended voting against the merger, and that Broadwood holds 27.5% of STAAR while Yunqi holds about 5.1%.
Yunqi Capital, a 5.1% shareholder of STAAR Surgical (NASDAQ: STAA), filed a Notice of Exempt Solicitation and released a letter urging STAAR’s Board to terminate the proposed merger with Alcon. The letter follows the Board’s postponement of the special meeting to December 3, 2025 and questions the adjournment and delay without substantive explanation.
Yunqi cites media reports that approximately 72% of outstanding shares voted against the merger and about 81% voted against a $55 million executive compensation package, and notes that ISS, Glass Lewis, and Egan-Jones recommended voting against the deal. The letter states no improved consideration has been disclosed in recent discussions with Alcon and asks the Board to end the process and refocus on STAAR’s long-term prospects.
STAAR Surgical Company postponed its special stockholder meeting to vote on adopting the Agreement and Plan of Merger with Alcon to December 3, 2025 at 8:30 a.m. Pacific Time. The meeting had been previously adjourned to November 6, 2025.
The new record date is October 24, 2025, and stockholders of record as of that date may vote at the rescheduled meeting. The company noted that a definitive proxy statement on Schedule 14A was filed on September 16, 2025, and referenced standard forward‑looking risk factors related to stockholder approval, regulatory clearances, and closing conditions.
The announcement was made via press release attached as Exhibit 99.1. The communication states it is not an offer or solicitation.
STAAR Surgical received a Notice of Exempt Solicitation from Yunqi Capital, a 5.1% shareholder, opposing the adjournment of STAAR’s special meeting to vote on the proposed sale to Alcon. The meeting was moved to November 6, 2025, from an earlier date tied to terms first announced on August 5, 2025.
In a letter attached to the filing, Yunqi urges the Board to let shareholders vote and to avoid launching a rushed process or new “go‑shop.” Yunqi frames Alcon’s proposal as a $28 per share offer and argues that any additional process should occur only after the current merger agreement ends, with a fuller market canvass. The investor also highlights its view of improving ICL market conditions in China and asks the Company to disclose in‑market ICL sales volumes to better reflect demand trends.
The submission emphasizes that it is not a proxy solicitation and that Yunqi is not seeking proxy cards.
Broadwood Partners, which owns 27.5% of STAAR Surgical’s common stock, is waging an active proxy campaign against STAAR’s proposed sale to Alcon. Broadwood is soliciting votes on its GREEN proxy card for the special meeting of shareholders scheduled for October 23, 2025, where investors will vote on the transaction. Broadwood strongly opposes the deal and highlights that all three major proxy advisory firms have recommended voting against it.
Broadwood also criticizes the agreement by STAAR and Alcon to postpone the final shareholder vote on the sale and argues that the delay creates uncertainty for the business. In response, Broadwood plans to seek a separate special meeting to remove three directors from STAAR’s board, including the chair and the CEO, and is directing shareholders to its campaign website, LetSTAARShine.com, for more information and voting instructions.
STAAR Surgical Company announced it has adjourned its special meeting of stockholders, originally set for October 23, 2025, to 8:30 a.m. Pacific Time on November 6, 2025. The meeting will consider, among other items, a proposal to adopt the Agreement and Plan of Merger entered on August 4, 2025 among STAAR, Alcon Research, LLC, and Rascasse Merger Sub, Inc.
The company noted that additional information is available in its definitive proxy statement filed on September 16, 2025, which was mailed to stockholders the same day. Documents are accessible at the SEC’s website and STAAR’s investor relations site.
STAAR Surgical (STAA): Broadwood Partners filed a definitive additional proxy solicitation (DFAN14A) alongside Amendment No. 39 to Schedule 13D and disclosed plans to call a separate special meeting to remove several directors. Broadwood reported beneficial ownership of 13,519,491 shares, representing
The filing highlights an already scheduled special meeting on
Yunqi Capital, a 5.1% shareholder of STAAR Surgical (STAA), filed an exempt solicitation and issued a letter urging the Board to hold the special meeting on October 23, 2025 as planned and stating it will vote against the proposed sale to Alcon.
The letter argues shareholders have enough information to decide and references company disclosures, including STAAR’s October 20 preliminary Q3 update. Yunqi highlights an estimated $54.4 million in China revenue for Q3 and about $142.6 million for the first three quarters of 2025 after adjustments, contending this reflects resilient end-demand in China. It also calls for more disclosure on margins and profitability and notes $25.6 million of consignment revenue referenced in the update.
Yunqi reiterates opposition to the deal terms announced on August 5, 2025 and encourages a timely vote, while outlining its view of STAAR’s long‑term prospects and governance steps the Board could consider after the vote.
Broadwood Partners filed additional proxy materials (DFAN14A) regarding STAAR Surgical Company, attaching a press release and updated website, and urging stockholders to vote “AGAINST” the proposed acquisition by Alcon at the virtual Special Meeting on October 23, 2025 at 8:30 a.m. Pacific Time.
Broadwood states that leading proxy advisory firms ISS, Glass Lewis, and Egan‑Jones have been cited in support of its position, and notes that shareholders representing more than
STAAR Surgical Company reported that it issued a press release with preliminary net sales results for the quarter ended September 26, 2025. The press release is furnished as Exhibit 99.1 to this report.
This update is an early look at sales performance for the most recent quarter and directs readers to the attached exhibit for specific figures and details.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
